2013-12-23 17:09:59 - New Pharmaceuticals market report from MarketLine: "Orphan Drugs: Rescue from the patent cliff"
Orphan drugs treat diseases that affect fewer than 1 in 2,000 Europeans & fewer than 200,000 Americans. Research into orphan drugs benefits from incentives provided by the 1983 Orphan Drug Act, such as tax breaks, faster regulatory reviews and assistance from FDA reviewers. Orphan drugs are less likely to face competition and provide a high return on investment. Cinryze costs $487,000 annually.
Features and benefits
* This reports looks at big pharma and how it has been affected by the patent cliff and the patent-loss of many of its biggest-selling blockbuster drugs
* Orphan drugs are granted certain incentives at the development stage, which encourages Big Pharma to invest in them.
* Orphan drugs can be very lucrative as companies can
charge a large amount for them. Much of the costs are covered by governments/insurance companies
Full Report Details at
- www.fastmr.com/prod/759018_orphan_drugs_rescue_from_the_patent_c ..
Global orphan drug sales increased at a rate of 7.1% to be worth $83bn in 2012 compared to the previous year. Orphan drugs are expected to bring in revenues of $127bn by 2018 and will account for almost 16% of total prescription drug sales, compared to 12.9% in 2012.
The most expensive drug in the world in 2013, Cinryze, is used by patients with hereditary angioedema, and is sold by ViroPharma. The drug's annual cost per patient is $487,000 per year. The second most expensive drug, Soliris, is sold by Alexion Pharmaceuticals, treats patients with paroxysmal nocturnal hemoglobinuria, & costs $486,000 annually.
According to patient advocacy group, Eurodis, around one third of EU patients can't get access to, or have difficulty accessing, the orphan drug they need.
Your key questions answered
* What drugs have lost their patents/are due to lose their patents, and what are they worth?
* Why is the orphan drug market attractive to pharmaceuticals companies?
* How have companies attempted to enter this market?
* Are the high prices of orphan drugs sustainable?
Report Table of Contents:
Big Pharma has been affected by the aEURœpatent cliffaEUR
The pharmaceuticals industry develops and markets drugs
aEURœBig PharmaaEUR are the largest pharmaceuticals companies, such as Pfizer and Novartis AG
The pharma industry has been affected by the aEURœpatent cliffaEUR
The patent cliff is still an issue
CompaniesaEUR reactions to the patent cliff have been diverse
Pharmaceuticals companies are increasingly investing in aEURœorphanaEUR drugs
Diseases are defined as aEUR˜rareaEUR when their prevalence is below a certain threshold
The Orphan Drug Act was passed to increase investment in the drugs needed to treat rare diseases
Orphan drugs have a significant return on investment
Shire Plc acquired ViroPharma in November
Sanofi bought Genzyme in
Pfizer created a new unit specializing in rare diseases in
Small pharma companies join big pharma in the top 20 orphan drugs sellers
Are the high prices of orphan drugs sustainable?
Orphan drugs are extremely expensive
European governments are focused on price, and drug availability is a problem
The orphan drug market is predicted to continue to grow at a strong rate
Ask the analyst
MarketLine is a global publisher of company, industry and country information. Their clients operate across a wide variety of industries and job functions and range from multinational corporations right down to small businesses in both developed and developing economies. MarketLine users enjoy access to content that is trustworthy, up to date and reasonably priced and routinely turn to them as their first-stop resource for instantly accessible, reliable business information. View more research from MarketLine at www.fastmr.com/catalog/publishers.aspx?pubid=1034
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.